Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Singer

Showing results (741-750 of 771) with videos related to

Pageof 78
Sort By:
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Circulation. Arrhythmia and Electrophysiology|April 17, 2020
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AFBenjamin A Steinberg, DaJuanicia N Holmes, Karen Pieper, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
JAMA Cardiology|November 13, 2017
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry StudyTaku Inohara, Peter Shrader, Karen Pieper, et al.
American Heart Journal|November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillationZak Loring, Peter Shrader, Larry A Allen, et al.
Pageof 78

Showing results (741-750 of 771) with videos related to

Sort By:
Pageof 78
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Circulation. Arrhythmia and Electrophysiology|April 17, 2020
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AFBenjamin A Steinberg, DaJuanicia N Holmes, Karen Pieper, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
JAMA Cardiology|November 13, 2017
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry StudyTaku Inohara, Peter Shrader, Karen Pieper, et al.
American Heart Journal|November 12, 2019
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillationZak Loring, Peter Shrader, Larry A Allen, et al.
Pageof 78